|
| Instrument | Goals | Cancer specific | Melanoma specific | Survivor-specific | Subscales | Remarks |
|
| EORTC QLQ-C30 [28] | Global HRQOL | yes | no | no | 5 functional scales: physical, emotional, role, cognitive
9 symptom scales: fatigue, pain, nausea, dyspnea, appetite loss, insomnia, constipation, diarrhea
1 summary scale.
30 items | Possible lack of sensitivity for use in melanoma survivors to evaluate HRQOL [41].
Symptoms not specific for melanoma survivors.
Not validated in cancer survivorship or in melanoma patients. |
|
| FACT-General [30] | Global HRQOL | yes | no | no | 4 functional scales: physical, emotional, social, functional wellbeing.
27 items | Can be completed by the FACT-M scale. |
|
| FACT-Melanoma [31] | Global HRQOL | yes | yes | no | 3 functional scales: physical, emotional, social, wellbeing.
27 items FACT-G + 24 FACT-M items | Melanoma specific with a specific post-surgery scale. Validated in all stages of melanoma. |
|
| Assessment of QLQ-8 [61] | Global HRQOL | yes | no | no | 8 dimensions:
3 physical dimensions (independent living, pain, senses) and 5 mental dimensions (mental health, happiness, coping, relationships, self-worth).
35 items | Is sensitive to changes in mental and emotional health.
May also be useful to capture the benefit of psychological interventions and to measure their cost effectiveness. |
|
| Impact of cancer (IOC) [29] | Global HRQOL | no | no | no | 8 scales: physical functioning, vitality, social functioning, general health, bodily pain, physical and emotional role, mental health.
37 items | Adjustment to changes.
Measures positive as well as negative impact of cancer. Not validated in cancer survivorship. |
|
| Lymphedema and Breast Cancer questionnaire (LBCQ) [54] | Symptoms and signs of lymphedema | yes | no | no | Assessment of 19 signs and symptoms.
59 items | Used in clinical practice to follow up lymphedema.
Can be useful in melanoma survivors as lymphedema impacts on HRQOL and wellbeing [38, 44, 45]. Not validated in the melanoma survivorship setting. |
|
| PHQ-9 [51] | Depression | no | no | no | Assessment depressive symptoms.
9 items | Screening for depressive symptoms. Widely used in survivorship trails. |
|
| General anxiety disorder GAD-7 [52] | Anxiety | no | no | no | Screening for General Anxiety Disorder (GAD).
7 items | It is not yet known that GAD is present in metastatic melanoma survivors. Not validated in cancer survivorship. |
|
| Mental Adjustment to Cancer Scale [56] | Adjustment to cancer | yes | no | no | Measures fighting spirit, anxious preoccupations, helplessness and loneliness and fatalism.
Updated scale includes also global adjustment to cancer.
40 items | Satisfactory measure of psychosocial outcome during the disease phase. Not validated in cancer survivorship. |
|
| Mental Health Inventory [57] | Psychological distress and wellbeing | no | no | no | Assessment of anxiety, depression, behavioral control, positive affect and general distress.
Original 38 items, revised version with 18 items. | Allows screening of emotional distress as well as behavioral aspects.
Widely used in the field of cancer. Not validated in cancer survivorship. |
|
| Fear of cancer recurrence (FCRI) [62] | Fear for cancer recurrence | yes | no | yes | Evaluates severity, triggers, psychological distress, coping strategies, insight and functional impairments.
42 items | Allows evaluating fear of recurrence of disease, which is in particular of interest in metastatic melanoma treated with immunotherapy in view of the high risk of recurrence, however not validated in melanoma setting. |
|
| Distress thermometer [64] | Distress | yes | no | no | Five categories: practical, family, physical and emotional problems, spiritual and religious concerns.
35 items | Useful and easy to use screening tool for emotional distress in clinical practice.
Reliably identifies distress in melanoma patients [63]. |
|
